Use of therapeutic drug monitoring for multidrug-resistant tuberculosis patients

Chest

Volumn 126, Issue 6, 2004, Pages 1770-1776

  Li, Jiehui ^a   Burzynski, Joseph N ^a   Lee, Yi An ^a   Berg, Debra ^a   Driver, Cynthia R ^a   Ridzon, Renee ^b   Munsiff, Sonal S ^a  

^a NEW YORK CITY DEPARTMENT OF HEALTH AND MENTAL HYGIENE   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Drug monitoring; Multidrug resistant tuberculosis

Indexed keywords

CIPROFLOXACIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; OFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIUM ISOLATE; BLOOD SAMPLING; CHILD; COMPARATIVE STUDY; CONTROLLED STUDY; DEMOGRAPHY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG WITHDRAWAL; FEMALE; HEALTH CENTER; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; PATIENT CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 10444258980     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.126.6.1770     Document Type: Article

References (25)

1. Peloquin CA. Therapeutic drug monitoring: principles and applications in mycobacterial infections. Drug Ther 1992; 22:31-36
2. Hong Kong Chest Service/BMJ Research Council. Five-year follow-up of a controlled trail of five 6-month regimens of chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis 1987; 136:1339-1342
3. Long MW, Snider DE, Farer LS. U.S. public health service cooperative trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis. Am Rev Respir Dis 1979; 119:879-894
4. Kimerling ME, Phillips P, Patterson P, et al. Low serum antimycobacterial drug concentrations in non-HIV infected tuberculosis patients. Chest 1998; 113:1178-1183
5. Frieden TR, Sterling T, Pablos-Mendez A, et al. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 1993; 328:521-526
6. Simone PM. Multidrug-resistant tuberculosis. In: Andriole VT, ed. Mediguide to infectious diseases. New York, NY: Lawrence DellaCorte Publications, 1994; 1-9
7. Iseman MD. Treatment of multidrug resistant tuberculosis. N Engl J Med 1993; 329:784-791
8. Peloquin CA, Using therapeutic drug monitoring to dose the antimycobacterial drugs. Clin Chest Med 1997; 18:79-87
9. Peloquin CA. Pharmacological issues in the treatment of tuberculosis. Ann N Y Acad Sci 2001; 953:157-164
10. Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002; 62:2169-2183
11. Kent PT, Kubica GP. Public health mycobacteriology: a guide for the level III laboratory. Atlanta, GA: Division of Laboratory Training and Consultation, Laboratory Program Office, US Department of Health and Human Services, Public Health Service, Centers for Disease Control, 1985
12. Schumacher GE, Barr JT. Economic and outcome issues for therapeutic drug monitoring in medicine. Ther Drug Monit 1998; 20:539-542
13. Bootman JL, Wertheimer AI, Zaske D, et al. Individualizing gentamicin dosage regimens in burn patients with gram-negative septicemia: a cost-benefit analysis. J Pharm Sci 1979; 68:267-272
14. Gardner DM, Hardy BG. Cost-effectiveness of therapeutic drug monitoring. Can J Hosp Pharm 1990; 1:7-12, xii
15. Ray J, Gardiner I, Marriott D. Managing antituberculosis drug therapy by therapeutic drug monitoring of rifampicin and isoniazid. Intern Med J 2003; 33:229-234
16. Berning SE. The role of fluoroquinolones in tuberculosis today. Drugs 2001; 61:9-18
17. Albert RK, Sbarbaro JA, Hudson LD, et al. High-dose ethambutol: its role in intermittent chemotherapy; a six-year study. Am Rev Respir Dis 1976; 114:699-704
18. Schoenenberger RA, Tanasijevic MJ, Jha A, et al. Appropriateness of antiepileptic drug level monitoring. JAMA 1995; 274:1622-1626
19. Schumacher GE, Barr JT. Total testing process applied to therapeutic drug monitoring: impact on patients' outcomes and economics. Clin Chem 1998; 44:370-374
20. Schumacher GE, Barr JT. Therapeutic drug monitoring: do the improved outcomes justify the costs? Clin Pharmacokinet 2001; 40:405-409
21. Destache CJ. Use of therapeutic drug monitoring in pharmacoeconomics. Ther Drug Monit 1993; 15:608-610
22. Bertrino JS, Rodvold KA, Destache CJ. Cost considerations in therapeutic drug monitoring of aminoglycosides. Clin Pharmacokinet 1994; 26:71-81
23. Peloquin CA, Namdar R, Singleton MD, et al. Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. Chest 1999; 115:12-18
24. Peloquin CA, Namdar R, Dodge AA, et al. Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids. Int J Tuberc Lung Dis 1999; 3:703-710
25. Centers for Disease Control and Prevention. Treatment of tuberculosis: American Thoracic Society, CDC, and Infectious Diseases Society of America. MMWR Morb Mortal Wkly Rep 2003; 52(RR-11):44